The overall goal of this proposal is to investigate mechanisms by which sex hormones favorably alter lipoprotein metabolism to protect women from coronary heart disease. The mechanisms by which estrogen raises triglyceride and HDL levels, and lowers LDL levels, and the mechanisms by which androgenic progestins have the opposite effects will be studied. The effects of sex hormones on VLDL, LDL and HDL metabolism, in vivo, will be determined by endogenous stable isotope labeling of apolipoproteins A-I and B. These studies measure the rates of production, clearance and interconversion of light and dense VLDL subfractions, IDL, and light and dense LDL subfractions, and apo E-containing particles. Multiple potential control points of apo B metabolism may therefore be identified. HDL metabolism will be studied similarly, and will analyze the relationships between immunochemically defined subfractions that contain apo A-I but not apo A-II, apo A-I with apo A-II, and apo E. Lipoprotein metabolism will be assessed during the following three crossover studies. (1) Oral estradiol. Fifteen healthy postmenopausal women will receive oral 17-beta estradiol 2mg daily or placebo. (2) Progestins. Androgenic progestins, such as levonorgestrel, are used in oral contraceptives and with estrogen in postmenopausal hormonal replacement. To distinguish between its androgenic and progestational effects, levonorgestrel will be compared to oral progesterone and to placebo in fifteen healthy postmenopausal women. (3) Induction of hypoestrogenism. Menopause is associated with deleterious effects on plasma triglyceride, LDL and HDL levels. To determine if these effects are caused by hypoestrogenism, per se, rather than by other processes, such as aging, hypoestrogenism will be induced by administering leuprolide, a long- acting gonadotropin-releasing-hormone agonist, or placebo to fifteen women. Taken together, this series of protocols will define estrogenic, androgenic, and progestational effects on specific mechanisms that control the metabolism of apo A-I and B. The findings will also help to define atherogenic and protective mechanisms in lipoprotein metabolism, and the mechanisms that underlie the difference in coronary heart disease rates between women and men. The study also will provide information to guide clinicians in the use of estrogen and progesterone in postmenopausal women.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034980-06
Application #
2217691
Study Section
Metabolism Study Section (MET)
Project Start
1986-09-01
Project End
1996-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Desai, Nirav K; Ooi, Esther M; Mitchell, Paul D et al. (2015) Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans. Atherosclerosis 241:326-33
Zheng, Chunyu; Khoo, Christina; Furtado, Jeremy et al. (2010) Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121:1722-34
Mendivil, Carlos O; Zheng, Chunyu; Furtado, Jeremy et al. (2010) Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 30:239-45
Zheng, Chunyu; Khoo, Christina; Furtado, Jeremy et al. (2008) Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am J Clin Nutr 88:272-81
Zheng, Chunyu; Khoo, Christina; Ikewaki, Katsunori et al. (2007) Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 48:1190-203
Campos, H; Perlov, D; Khoo, C et al. (2001) Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 42:1239-49
Tomiyasu, K; Walsh, B W; Ikewaki, K et al. (2001) Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol 21:1494-500
Khoo, C; Campos, H; Judge, H et al. (1999) Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. J Lipid Res 40:202-12
Walsh, B W; Spiegelman, D; Morrissey, M et al. (1999) Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol. J Clin Endocrinol Metab 84:985-9
Su, W; Campos, H; Judge, H et al. (1998) Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab 83:3267-76

Showing the most recent 10 out of 18 publications